Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from IXICO plc ( (GB:IXI) ).
IXICO plc announced a trading update for the financial year ended September 30, 2025, reporting a 13% increase in revenues to £6.5 million, exceeding market expectations. The company secured new contracts and extended existing ones, contributing to a year-end order book of £13.8 million. With a year-end cash position of £3.5 million, IXICO also completed a capital raise, enabling investments in growth areas. The company anticipates a slightly improved EBITDA loss of no more than £1.6 million, reflecting strategic investments aimed at sustaining growth. CEO Bram Goorden expressed optimism about continued growth and value creation in the neurodegenerative disease biopharma R&D market.
The most recent analyst rating on (GB:IXI) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.
Spark’s Take on GB:IXI Stock
According to Spark, TipRanks’ AI Analyst, GB:IXI is a Neutral.
The overall stock score reflects significant financial challenges, including declining revenue and negative profit margins. Despite strong technical momentum, the stock’s valuation is unattractive due to negative earnings and lack of dividends. The absence of earnings call and corporate events data limits further insights.
To see Spark’s full report on GB:IXI stock, click here.
More about IXICO plc
IXICO plc is a global leader in neuroscience imaging and biomarker analytics, utilizing its AI-driven platform to advance drug development in neurological disorders. As an end-to-end Imaging Contract Research Organisation (iCRO), IXICO collaborates with leading pharmaceutical companies, biotech firms, disease consortia, and non-profit organizations to support neurological clinical trials, focusing on diseases such as Alzheimer’s, Huntington’s, and Parkinson’s.
Average Trading Volume: 86,127
Technical Sentiment Signal: Hold
Current Market Cap: £11.12M
Find detailed analytics on IXI stock on TipRanks’ Stock Analysis page.